Navigation Links
Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
Date:11/10/2008

this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals.

To date, over 1,700 patients have been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine are nausea, vomiting, diarrhea and fatigue, but these are either mild or non-existent in lower doses that have induced tumor regression. Responses have been seen with both daily and weekly regimens. At the doses studied, the daily regimens were better tolerated.

In Phase 1/2 trials, KRX-0401 has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and hepatocel
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
6. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
7. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
8. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
9. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
10. Lippincott Williams & Wilkins Selected as Publisher of the Journal of Neuroscience Nursing
11. Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... ... Constitution, the new Lifetime reality series, “Atlanta Plastic” is getting attention for moving ... plastic surgery, with its predominantly African-American cast of doctors and patients. Beverly Hills ...
(Date:8/3/2015)... ... August 03, 2015 , ... They know every second counts. And when ... Center offers some of the best care in the nation. For the past two ... fastest average blood clot removal time in the country. During the months of June ...
(Date:8/3/2015)... ... August 03, 2015 , ... Kantor ... in favor of the firm’s client Rebecca Hamsher, deciding that in accordance with ... reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other mental health ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3
... ― As part of preparations for a possible large-scale ... local levels should determine where and how anthrax-preventing antibiotics ... report from the Institute of Medicine. The report ... with the federal government to assess the benefits and ...
... a promising yet volatile French SME in the medical ... The seven founders teamed-up with Grard Heinrich, an experienced ... Ventures, an investment fund specialising in start-up support. Now ... are backing CrossJect, which is awaiting favourable conditions for ...
... pressure to share sexual images via the new phenomenon of ... found. ,Sexting, is the practice of sending and receiving ... is one of the first academic investigations into ,sexting, from ... to the 2011 Australasian Sexual Health Conference in Canberra. ...
... (HealthDay News) -- Yawning may be a natural way of ... examined the frequency of yawns among 80 people in the ... seasonal variations. Yawning is known to be "contagious," the ... yawning, nearly half of the participants yawned while outdoors in ...
... at least on the healthy part. "Early to bed and early ... youths keep slimmer and more physically active than their night-owl peers, ... A study in the Oct. 1 issue of the journal ... participants, ages 9 to 16, and compared their weights and uses ...
... , THURSDAY, Sept. 29 (HealthDay News) -- Men over ... undertreated for their condition, according to a new study. ... by other health problems -- or "co-morbid" conditions -- are ... as expected, University of California, Los Angeles researchers found. ...
Cached Medicine News:Health News:Community storage of anthrax-preventing antibiotics should be determined by state 2Health News:Community storage of anthrax-preventing antibiotics should be determined by state 3Health News:An innovation star for Europe 2Health News:An innovation star for Europe 3Health News:'Sexting' driven by peer pressure 2Health News:Yawning May Help the Brain Chill Out 2Health News:Early to bed and early to rise -- study suggests it's keeping kids leaner 2Health News:Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study 2Health News:Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study 3
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... 2015 Global physiotherapy ... USD 24.7 billion by 2022, according to a ... prevalence of neurological and musculoskeletal disorders are expected ... forecast period. The presence of efficient and effective ... the technologies coupled with implementation of favorable government ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
... the active lifestyle, the Chesterfield ... for men, women and children., ... wide variety of design options, ... young, relaxed attitude, and children ...
Inquire...
... doctors, tests for elevated thyroid stimulating hormone ... the first clinical indicator of hypothyroidism. , ... to use, cost effective and accurate. ... programs and health promotion. , ThyroChek is CLIA ...
VertiGraft allografts for spine surgery deliver the strength adn performance you demand in your procedures and they are backed by quality and safety standards that are unmatched in the industry....
Medicine Products: